NCT07151703 Topical Versus Injection PRP for Olfactory Dysfunction
| NCT ID | NCT07151703 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Taipei Veterans General Hospital, Taiwan |
| Condition | Olfactory Dysfunction |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-09-11 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 60 participants in total. It began in 2025-09-11 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to determine whether two different delivery methods of autologous platelet-rich plasma (PRP) can improve olfactory function in adults with persistent olfactory dysfunction lasting more than three months. The main questions it aims to answer are: 1. Does carrier-assisted topical application of PRP lead to comparable or better improvement in smell function than intranasal injection of PRP? 2. Which method provides greater patient comfort and fewer adverse effects? Researchers will compare carrier-assisted topical PRP application to intranasal PRP injection to see if one approach is more effective in restoring olfactory function. Participants will: 1. Receive a single PRP treatment delivered either by injection or via a PRP-soaked carrier placed into the olfactory cleft. 2. Continue daily olfactory training for three months following the intervention. 3. Undergo smell testing (Sniffin' Sticks) before and after treatment and complete quality-of-life questionnaires.
Eligibility Criteria
Inclusion Criteria: * Aged between 18 and 80 years, regardless of sex * Subjective complaint of olfactory dysfunction with confirmed hyposmia or anosmia based on standardized olfactory testing * History of at least 3 months of prior olfactory training but with persistent olfactory complaints Exclusion Criteria: * Congenital anosmia * Diagnosed neurological or structural brain abnormalities (e.g., brain tumor, major head trauma, stroke) with low likelihood of olfactory recovery * Inability or unwillingness to comply with study procedures or follow-up assessments
Contact & Investigator
Dr. Yun-Ting Chao Principal Investigator (Attending Physician and Head of Dep.), PhD
✉ yunting001@gmail.com📞 886-2-2875-7337
Frequently Asked Questions
Who can join the NCT07151703 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Olfactory Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07151703 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 60 participants.
Is NCT07151703 currently recruiting?
Yes, NCT07151703 is actively recruiting participants. Contact the research team at yunting001@gmail.com for enrollment information.
Where is the NCT07151703 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT07151703 clinical trial?
NCT07151703 is sponsored by Taipei Veterans General Hospital, Taiwan. The trial plans to enroll 60 participants.